BioStock: Cyxone's new management in place for the next phase

During the first half of 2020, Malmö based company Cyxone has strengthened its management team with a new COO and a new CEO. Through existing and new collaborations, the company has also begun to explore expanded and new indication areas, while also focusing on pushing the clinical development programs towards the next phase. The market’s appreciation of the company’s work has rewarded the share with an almost 50 percent share price increase during the first six months of the year.

Read the full article about Cyxone at

This is a press release from BioStock - Connecting Innovation & Capital


About Us

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50,


Quick facts

Cyxone's new management in place for the next phase
Tweet this